In conclusion, our findings indicate that signaling cues triggered by the N-terminal TSP-1 domain of short ColXVIII and transmitted through ErbBs and/or integrins can potentiate BC cell functions and promote the development of drug resistances, especially in advanced HER2-type BC (Figure 8B and Supplemental Figure 14F). Here, ERBB2 is linked to breast cancer.